<DOC>
	<DOCNO>NCT02561936</DOCNO>
	<brief_summary>The purpose study compare rate extent absorption rilpivirine healthy adult participant follow : 1 ) administration single dose two different oral dispersible tablet formulation candidate oral granule formulation follow administration single dose 25-milligram ( mg ) oral tablet ( EDURANT ) , standardize breakfast ; 2 ) administration single dose one select oral formulation candidate ( dispersible tablet granule ) different feed condition ( standardize breakfast yoghurt ) fast state breakfast 3 ) administration single dose one select oral formulation candidate ( dispersible tablet granule ) disperse water orange juice , feed condition ( standardized breakfast ) .</brief_summary>
	<brief_title>Relative Bioavailability Three Oral Formulations Candidates Rilpivirine Potential Pediatric Use Compared Oral Tablet</brief_title>
	<detailed_description>This Phase 1 , open-label , randomize , 2-panel , 4-way crossover study healthy adult participant assess relative bioavailability rilpivirine follow single dose administration oral pediatric formulation candidate ( two dispersible tablet formulation one granule formulation ) , compare commercially available 25-mg tablet ( EDURANT ) ass effect food different food constituent oral bioavailability rilpivirine follow single dose administration one select formulation candidate . The study consist 2 panel : Panel 1 Panel 2 . In panel , participant randomize receive treatment A , B , C , D E , F , G , H , respectively . Pharmacokinetic parameter evaluate primarily . Safety monitor throughout study .</detailed_description>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Participants must willing able adhere prohibition restriction specify protocol study procedure Participant must healthy basis medical evaluation reveals absence clinically significant abnormality include physical examination , medical history , vital sign , electrocardiogram ( ECG ) , result blood biochemistry hematology test urinalysis perform screening . If abnormality , participant may include Investigator judge abnormality deviation normal clinically significant . This determination must record participant 's source document initial Investigator Female participant must either postmenopausal ( amenorrhea least 2 year serum folliclestimulating hormone [ FSH ] level great equal ( &gt; ) 40 international unit per liter ( IU/L ) [ confirm screen postmenopausal woman ] ) , OR permanently sterilize ( eg , bilateral tubal occlusion [ include tubal ligation procedure consistent local regulation ] , total hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) otherwise incapable become pregnant , negative serum pregnancy test screen Male participant heterosexually active woman childbearing potential must agree use two effective contraceptive method study least 90 day receive last dose study drug male participant must agree donate sperm study least 90 day receive last dose study drug Participants must nonsmoking least 3 month prior Screening Female participant breastfeed Screening Participants history illness , opinion Investigator , might confound result study pose additional risk administer study drug participant could prevent , limit confound protocol specify assessment . This may include , limited , renal dysfunction , significant cardiac , vascular , pulmonary , gastrointestinal ( significant diarrhea , gastric stasis , constipation Investigator 's opinion could influence drug absorption bioavailability ) , endocrine , neurologic , hematologic , rheumatologic , psychiatric , neoplastic , metabolic disturbance Participants current hepatitis B infection ( confirm hepatitis B surface antigen [ HBsAg ] ) hepatitis C infection ( confirm hepatitis C virus [ HCV ] antibody ) , human immunodeficiency syndrome1 ( HIV1 ) HIV2 infection Participants history drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 5th edition ) ( DSMV ) criterion within 5 year screen positive test result ( ) alcohol and/or drug abuse ( include barbiturate , opiate , cocaine , amphetamine , methadone , benzodiazepine , methamphetamine , tetrahydrocannabinol , phencyclidine , tricyclic antidepressant ) Screening Participants history clinically relevant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticaria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>EUDRANT</keyword>
	<keyword>Rilpivirine</keyword>
</DOC>